© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
All News
Asian Americans Have Higher COVID-19 Case-Fatality Rates in Many States, Localities
July 14, 2020
The higher case-fatality rate could be because of low resting rates, a greater number of deaths, or both,
Do DMTs Increase the Risk of COVID-19 for MS Patients?
July 13, 2020
At the start of the COVID-19 pandemic, some feared patients with multiple sclerosis who were taking disease-modifying therapies might be at a higher risk of infection or case severity. A smalll study suggests that may not the case with one of them.
Unlocking The Power of Data Intelligence for The Pharmacy
July 13, 2020
From staffing to readmissions to diagnostics, data intelligence is poised to revolutionize healthcare.
Is Combination Therapy on the Horizon in Diabetic Macular Edema?
July 12, 2020
Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.
Patient-Centered Medical Home Repair: Flat Fee Reduces Imaging Volume
July 11, 2020
Study of program in Oregon suggests that fee-for-service may be the reason for the underwhelming results for patient-centered medical homes.
CMS Says Agency Is Sending Quality Improvement Help to Nursing Homes In COVID-19 Hotspots
July 10, 2020
Federal agency is dispatching Quality Improvement Organizations to hotspots.
TRHC Expands Clinical Services to Include MA Enrolled High-Risk, Special Needs Patients
July 10, 2020
The healthcare tech company will assist health plans in meeting Care for Older Adults requirements.
Lisa Griffin of Jefferson Health Talks Race and Inequity (Pt. 3)
July 10, 2020
Peter Wehrwein, senior editor at Managed Healthcare Executive, spoke with Lisa Griffin, senior vice president of front-end operations at Jefferson Health in Philadelphia, about the pivot to telehealth, "seamless access" and racism.
Biosimilars for Cancer an 'Emerging Success' Says NCCN's Koh
July 09, 2020
Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.